ArriVent BioPharma Lung Cancer Drug Fails Phase 3 Trial
ArriVent BioPharma announced that its experimental treatment for a type of lung cancer did not meet the primary endpoint in a Phase 3 clinical trial. The company's stock fell 59% in premarket trading following the news.
ArriVent BioPharma said a treatment it is developing for a type of lung cancer failed to meet the primary endpoint in a Phase 3 trial. 77 in premarket trading on Tuesday. At Monday’s market close, shares were up 41% year to date. The biopharmaceutical company…